A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Males and Females (not nursing or not pregnant)

• 18-75 years of age

• Diagnosis of moderate to severe psoriasis for at least six months at the time of screening

• Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies